NewAmsterdam Pharma Company N.V. (NAMS) Operating income 2021–2025
NewAmsterdam Pharma Company N.V. (NAMS) annual operating income history from SEC filings — each fiscal year as reported.
-$225.7MFY2025 · since FY2021: -$35.0M → -$225.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$225.7M | -28.0% |
| FY2024 | -$176.3M | +3.6% |
| FY2023 | -$183.0M | -5043.9% |
| FY2022 | -$3.6M | +89.8% |
| FY2021 | -$35.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating marginNAMS Operating cash flowNAMS Free cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →